AtaiBeckley (ATAI) Consolidated Net Income (2020 - 2026)
AtaiBeckley (ATAI) posted Consolidated Net Income of -$61.1 million for Q3 2025, down 120.04% sequentially from -$27.8 million in Q2 2025, and down 129.03% YoY from $210.3 million in Q3 2024.
Analysis
AtaiBeckley (ATAI) Consolidated Net Income (2020 - 2026) Analysis & Trends
AtaiBeckley's Consolidated Net Income history runs 2 years deep, the most recent figure standing at -$29.8 million for Q1 2026.
- In Q1 2026, Consolidated Net Income fell 12.61% year-over-year to -$29.8 million; the TTM figure through Mar 2026 stood at -$56.3 million (changed N/A YoY), while the FY2025 annual figure was -$659.9 million, down 344.64% from the prior year.
- Consolidated Net Income eased to -$61.1 million in Q3 2025 per ATAI's latest filing, from -$27.8 million in the prior quarter.
- The five-year high for Consolidated Net Income was -$26.5 million in Q1 2025, with the low at -$29.8 million in Q1 2026.
- A 5-year average of -$30.4 million and a median of -$31.8 million in 2023 frame the typical range for Consolidated Net Income.
- The sharpest annual moves came in 2021 and 2023: Consolidated Net Income plunged 842.61% in 2021, then soared 231.22% in 2023.
- Over 5 years, Consolidated Net Income stood at -$49.3 million in 2021, then increased by 18.3% to -$40.3 million in 2022, then soared by 53.45% to -$18.7 million in 2023, then plunged by 107.97% to -$39.0 million in 2024, then plunged by 56.62% to -$61.1 million in 2025.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$61.1 million, -$27.8 million, and -$26.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | AtaiBeckley | 1.60 Bn | 1.60 Bn | - | -61.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -32.58 Mn |
| Mar 31, 2026 | -29.98 Mn |
| Sep 30, 2025 | -61.10 Mn |
| Jun 30, 2025 | -27.75 Mn |
| Jun 30, 2025 | -27.75 Mn |
| Mar 31, 2025 | -26.47 Mn |
| Mar 31, 2025 | -26.51 Mn |
| Dec 31, 2024 | -38.63 Mn |
| Sep 30, 2024 | -26.66 Mn |
| Jun 30, 2024 | -57.18 Mn |
| Mar 31, 2024 | -25.68 Mn |
| Dec 31, 2023 | -18.74 Mn |
| Sep 30, 2023 | 43.61 Mn |
| Jun 30, 2023 | -31.86 Mn |
| Mar 31, 2023 | -33.36 Mn |
| Dec 31, 2022 | -45.32 Mn |
| Sep 30, 2022 | -33.27 Mn |
| Jun 30, 2022 | -30.86 Mn |
| Mar 31, 2022 | -31.96 Mn |
| Dec 31, 2021 | -52.14 Mn |